Introduction: Diabetes mellitus is considered an epidemic disease in the gulf countries. Its prevalence in Saudi Arabia is becoming the highest in the world affecting around 30% of adults (1), (3). Indeed, diabetes is associated with an elevated risk of cardiovascular disease (CVD). Therefore, management of diabetic dyslipidemia, a well-recognized and modifiable risk factor, is an essential factor in the multifactorial approach to prevent CVD in individuals with type 2 diabetes (4). Several meta-analyses studies have clearly shown the benefits of statin therapy (3). Aims: To assess the results of the prescription of simvastatin for patients with type 2 diabetes. Methods: A cross-sectional study of 168 diabetic patients was conducted in Hera General Hospital. Data were retrieved from medical records from January 2018 until December 2018. Data analysis was performed using Ecxelsoftwares. Results: Most of the sample population (95%) was older than 40 years old. Nearly all patients (97%) were on statin treatment. The treatment goal for LDL-c <2.5 mmol/l was achieved in 42 (21%) patients. Diabetic men were more likely than diabetic women to be given a prescription for a statin (P<0.05). Conclusion: Data from 2018 elucidate that diabetic patients at HGH were associated with a statin prescription. However, only a small proportion of patients with diabetes reaches the LDL-c treatment target. These results emphasize the need for better monitoring, better utilization of available medication and for new treatment options for a better quality of life.
IJCR is following an instant policy on rejection those received papers with plagiarism rate of more than 20%. So, All of authors and contributors must check their papers before submission to making assurance of following our anti-plagiarism policies.
